StockData
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. (GOSS) stock

GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$11.43+0.39 (+3.53%)

Close on Nov 18, 2026Market cap $5.59BP/E –Yield –

Gossamer Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Gossamer Bio's operating income for the twelve months ending Jun 30, 2026 was -$166.09M. For fiscal 2025 it was -$170.73M. The highest annual figure on record is -$6.65M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$170.73M–
FY2024Dec 31, 2024-$59.92M–
FY2023Dec 31, 2023-$183.76M–
FY2022Dec 31, 2022-$218.59M–
FY2021Dec 31, 2021-$216.12M–
FY2020Dec 31, 2020-$233.96M–
FY2019Dec 31, 2019-$186.14M–
FY2018Dec 31, 2018-$148.99M–
FY2017Dec 31, 2017-$6.65M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$26.07M–
Q1 FY2026Mar 31, 2026-$44.87M–
Q4 FY2025Dec 31, 2025-$46.04M–
Q3 FY2025Sep 30, 2025-$49.11M–
Q2 FY2025Jun 30, 2025-$38.77M-174.4%
Q1 FY2025Mar 31, 2025-$36.81M–
Q4 FY2024Dec 31, 2024-$36.13M–
Q3 FY2024Sep 30, 2024-$33.92M–
Q2 FY2024Jun 30, 2024$52.09M–
Q1 FY2024Mar 31, 2024-$41.96M–
Q4 FY2023Dec 31, 2023-$49.03M–
Q3 FY2023Sep 30, 2023-$40.49M–
Q2 FY2023Jun 30, 2023-$46.30M–
Q1 FY2023Mar 31, 2023-$47.94M–
Q4 FY2022Dec 31, 2022-$54.36M–
Q3 FY2022Sep 30, 2022-$56.02M–
Q2 FY2022Jun 30, 2022-$53.87M–
Q1 FY2022Mar 31, 2022-$54.34M–
Q4 FY2021Dec 31, 2021-$51.66M–
Q3 FY2021Sep 30, 2021-$55.66M–
Q2 FY2021Jun 30, 2021-$55.60M–
Q1 FY2021Mar 31, 2021-$53.20M–
Q4 FY2020Dec 31, 2020-$60.09M–
Q3 FY2020Sep 30, 2020-$53.57M–
Q2 FY2020Jun 30, 2020-$65.34M–
Q1 FY2020Mar 31, 2020-$54.97M–
Q4 FY2019Dec 31, 2019-$55.79M–
Q3 FY2019Sep 30, 2019-$49.99M–
Q2 FY2019Jun 30, 2019-$46.35M–
Q1 FY2019Mar 31, 2019-$34.02M–
Q4 FY2018Dec 31, 2018-$39.81M–
Q3 FY2018Sep 30, 2018-$50.02M–
Q2 FY2018Jun 30, 2018-$33.04M–
Q1 FY2018Mar 31, 2018-$26.13M–

More Gossamer Bio figures

See a number that looks wrong?